This conversation focuses on why it will be challenging to use currently-available NITs to stage patients with advanced MASH fibrosis (F2/F3) accurately with current test options.
This conversation focuses on why use of NITs is such a pivotal issue for MASH treatment and drug adoption, particularly if, as expected, the first MASH drug is approved this month.
In the podcast episode, panelists delve into the shifting landscape of diagnosing and treating F2/3 MASH patients using non-invasive tests (NITs). They discuss challenges with current diagnostic tools, upcoming blood-based tests, and the potential impact of new drugs like resmetirom and GLP-1s on treatment strategies, aiming to optimize changes in the industry once a drug is approved.
Hepatology researcher, key opinion leader and 2023 UEG Rising Star of the Year Hannes Hagstrom joins Louise Campbell and Roger Green in a far-ranging discussion focusing largely on issues in diagnostics and clinical care pathways.
Hepatology researcher and Key Opinion Leader Naim Alkhouri joins Louise Campbell and Roger Green to discuss advances in drug development and NITs and to share thoughts about efficacious use of clinical care pathways.
Patient advocates Mike Betel and Tony Villiotti join Jörn Schattenberg and Roger Green to discuss key events in MASLD 2023 from a patient point of view.
Surfing the MASH Tsunami kicks off its 2023 wrap-up conversations with Jeff Lazarus, the 2023 winner of the Distinguished Scientific Achievement Award from the American Liver Foundation. Wrapping up 2023 in Steatotic Liver Disease: A Discussion with Jeff Lazarus
Surfing NASH reviews the 2023 EASL SLD Summit in two interview sessions with meeting faculty members Sven Francque and Hannes Hagström. Co-host Jörn Schattenberg joins both conversations as a fellow presenter while Louise Campbell and Roger Green inject thought-provoking questions and perspectives to elicit a succinct snapshot of the event for our listeners.
In this episode From the Vault, Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from the 2021 Paris NASH meeting, an event with exciting scientific messages and insights. This episode has played out to be by far the most downloaded segment in the podcast’s history!
In this final conversation, the Surfers are joined by Veronica Miller to discuss the recent FDA workshop for NIT development. Veronica discusses her unique impressions on the workshop and steers the group to consider the question of “why are we validating a surrogate with a surrogate?”
